![(E)-[6]-Dehydroparadol](/upload/1124/V28977.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
(E)-[6]-Dehydroparadol targets the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2), a master regulator of the antioxidant response. It acts as a potent activator of Nrf2. By activating Nrf2, the compound induces the expression of antioxidant and cytoprotective genes, protecting cells from oxidative stress. The compound also has direct effects on cancer cells, inhibiting their growth and inducing apoptosis. Its mechanism involves both Nrf2-dependent and Nrf2-independent pathways in cancer cells.
|
|---|---|
| ln Vitro |
(E)-[6]-Dehydroparadol (M15) (5-80 µM; 24 h) stops HCT-116 and H-1299 cells from growing, having IC50 values of 43.02 and 41.59 µM, respectively[1]. (E)-[6]-Dehydroparadol (10–40 µM; 24 hours) causes HCT-116 and H-1299 cells to undergo apoptosis [1].
In vitro studies have shown that (E)-[6]-Dehydroparadol (5-80 uM) inhibits the growth and induces the apoptosis of human cancer cells. It is a potent Nrf2 activator. The compound's activity has been characterized in various cancer cell lines, demonstrating its potential as an anticancer agent. As an oxidative metabolite of [6]-shogaol, it represents a bioactive ginger-derived compound with significant biological activity. Its ability to activate Nrf2 suggests it may have protective effects against oxidative stress-related diseases. |
| ln Vivo |
(E)-[6]-DeHydroparadol (Compound 19) (5 µM; 24 hr) increases Tg[green fluorescent protein (GFP) in Tg(glutathione S-transferase pi 1 (gstp1):GFP) )] Transgenic zebrafish embryos with fluorescent signals [2].
In vivo studies of (E)-[6]-Dehydroparadol are limited, as the compound is primarily used as a research tool. Its potential as an anticancer agent has been suggested based on in vitro findings. As a Nrf2 activator, it could have protective effects in models of oxidative stress and inflammation. However, specific in vivo efficacy data are not extensively reported. Additional research is required to assess its efficacy and safety in vivo. The compound is for research use only. |
| Enzyme Assay |
The in vitro assay for (E)-[6]-Dehydroparadol depends on the biological activity being measured. For Nrf2 activation, a reporter gene assay is used: cells are transfected with an antioxidant response element (ARE)-luciferase reporter construct and treated with varying concentrations of the compound; luciferase activity is measured to quantify Nrf2 activation. For anticancer activity, cancer cells are treated with the compound (5-80 uM) and cell viability is assessed using MTT or CellTiter-Glo assays. Apoptosis is evaluated by measuring caspase activity or Annexin V staining.
|
| Cell Assay |
In vitro cellular assays for (E)-[6]-Dehydroparadol are conducted using human cancer cell lines. Cells are plated in multi-well plates and treated with varying concentrations of the compound (5-80 uM) for 24-72 hours. Cell viability is assessed using MTT, MTS, or CellTiter-Glo assays. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining or by measuring caspase-3/7 activity. Nrf2 activation is assessed by measuring the expression of Nrf2 target genes (e.g., HO-1, NQO1) by qRT-PCR or Western blot. All experiments are performed in triplicate with appropriate vehicle controls.
|
| Animal Protocol |
In vivo animal studies for (E)-[6]-Dehydroparadol are not extensively reported. As a Nrf2 activator and potential anticancer agent, it could be evaluated in mouse models of cancer or oxidative stress. Typical study designs would involve administration of the compound via oral gavage or intraperitoneal injection in tumor-bearing or disease model mice. Tumor growth, oxidative stress markers, and Nrf2 target gene expression would be assessed. However, specific published in vivo protocols for this compound are not available in the provided sources.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (E)-[6]-Dehydroparadol are not extensively reported. The compound has a molecular weight of 276.37 g/mol and a molecular formula of C17H24O3. As a phenolic compound, it is lipophilic and would be expected to be absorbed after oral administration. It is an oxidative metabolite of [6]-shogaol, suggesting it is formed in vivo from its parent compound. Specific pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution are not provided in the available sources.
|
| Toxicity/Toxicokinetics |
Toxicology data for (E)-[6]-Dehydroparadol are not extensively reported. As a ginger-derived compound, it is expected to have a favorable safety profile, but systematic toxicological studies have not been conducted. The compound's mechanism of action involves Nrf2 activation, which is generally considered cytoprotective. However, excessive Nrf2 activation could potentially have adverse effects. Specific toxicity data, including LD50 values and organ toxicity profiles, are not available. The compound is for research use only.
|
| References | |
| Additional Infomation |
Structure in the first source
(E)-[6]-Dehydroparadol is an oxidative metabolite of [6]-shogaol and a potent Nrf2 activator. It inhibits the growth and induces apoptosis of human cancer cells. The compound belongs to the vanilloid family of phenolic compounds found in ginger. It has a molecular weight of 276.37 g/mol and a molecular formula of C17H24O3. (E)-[6]-Dehydroparadol is a research tool for studying Nrf2 signaling, oxidative stress, and cancer biology. |
| Molecular Formula |
C17H24O3
|
|---|---|
| Molecular Weight |
276.37066
|
| Exact Mass |
276.173
|
| CAS # |
878006-06-5
|
| Related CAS # |
Paradol;27113-22-0
|
| PubChem CID |
6438480
|
| Appearance |
Yellow to orange solid powder
|
| LogP |
4.343
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
20
|
| Complexity |
299
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC(=O)/C=C/C1=CC(=C(C=C1)O)OC
|
| InChi Key |
AXMBOMODZLJDKX-PKNBQFBNSA-N
|
| InChi Code |
InChI=1S/C17H24O3/c1-3-4-5-6-7-8-15(18)11-9-14-10-12-16(19)17(13-14)20-2/h9-13,19H,3-8H2,1-2H3/b11-9+
|
| Chemical Name |
(E)-1-(4-hydroxy-3-methoxyphenyl)dec-1-en-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 140 mg/mL (~506.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6183 mL | 18.0917 mL | 36.1834 mL | |
| 5 mM | 0.7237 mL | 3.6183 mL | 7.2367 mL | |
| 10 mM | 0.3618 mL | 1.8092 mL | 3.6183 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
